Steven J Burakoff, MD
img_Steven J Burakoff
PROFESSOR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pediatrics, Hematology/Oncology
Research Topics
T Cells
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]
Major Research Interests:

   1. Cellular and molecular immunology;
   2. T cell activation and signal transduction;
   3. Transplantation immunology.

MA, Queens College

MA (hon), Harvard University

Harvard Medical School

New York Hospital-Cornell Medical Center

Rockefeller University

2009

Lifetime Achievement Award

American Association of Immunologists

2006

Lynne Cohen Foundation Awardee

2003

Distinguished Alumnus 2003

2002

Theobold Smith Alumni Lecture

Albany Medical College

2001

ISI Highly Cited Researcher (1980-2000)

2000

Laura and Isaac Perlmutter Professor

New York University, School of Medicine

1998

Margaret M. Dyson Professor of Pediatrics

Harvard Medical School

1995

Ted Williams Senior Investigator

Dana-Farber Cancer Institute

1995

Association of American Physicians

1994

Horizons in Biomedical Research Lecture

Cleveland Clinic Foundation

1992

David A. Talmadge Lecture

Colorado Allergy Society

Steven Burakoff, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Burakoff during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • Cullinan Oncology

Consulting:

  • Millbank

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Codegenix

Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Pfizer Inc.
  • Cell Source
  • DepYmed
  • codagenix

Scientific Advisory Board:

  • Damon Runyon Cancer Foundation
  • Cell Source

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.